Pam R Taub Selected Research

RNA (Ribonucleic Acid)

1/2021

COVID-19 Severity Potentially Modulated by Cardiovascular-Disease-Associated Immune Dysregulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pam R Taub Research Topics

Disease

15	Heart Failure 10/2021 - 04/2009
9	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 02/2013
6	Type 2 Diabetes Mellitus (MODY) 12/2019 - 02/2012
5	Inflammation (Inflammations) 12/2023 - 12/2015
5	Body Weight (Weight, Body) 10/2021 - 06/2010
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023 - 01/2013
4	COVID-19 01/2022 - 03/2020
4	Infarction (Infarctions) 01/2020 - 06/2010
3	Atherosclerosis 04/2024 - 01/2021
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 03/2024 - 12/2020
3	Coronary Artery Disease (Coronary Atherosclerosis) 03/2023 - 01/2021
2	Dyslipidemias (Dyslipidemia) 06/2024 - 01/2021
2	Hyperlipidemias (Hyperlipidemia) 03/2024 - 01/2021
2	Hypercholesterolemia 01/2023 - 12/2020
2	Hypertension (High Blood Pressure) 01/2022 - 02/2013
2	Obesity 01/2021 - 01/2018
2	Ulcerative Colitis 01/2021 - 01/2020
2	Heart Diseases (Heart Disease) 12/2020 - 05/2012
2	Insulin Resistance 01/2019 - 01/2018
2	Myocardial Infarction 01/2018 - 06/2010
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2013 - 04/2012
1	Pathologic Constriction (Stenosis) 04/2024
1	Peripheral Arterial Disease 03/2024
1	Obstructive Sleep Apnea 01/2023
1	Pulmonary Hypertension 01/2023
1	Tachycardia (Tachyarrhythmias) 11/2022
1	Cognitive Dysfunction 01/2022
1	Post-Acute COVID-19 Syndrome 01/2022
1	Myocarditis (Carditis) 01/2022
1	Prediabetic State (Prediabetes) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Hypoglycemia (Reactive Hypoglycemia) 01/2022
1	Overweight 10/2021
1	Abdominal Obesity 01/2021
1	Postural Orthostatic Tachycardia Syndrome 01/2021
1	Bradycardia 01/2021
1	Rheumatoid Arthritis 01/2021
1	Hypotension (Low Blood Pressure) 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021
1	Sinus Tachycardia 01/2021
1	Supraventricular Tachycardia 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Diabetes Mellitus 01/2019
1	Weight Gain 01/2018
1	Injection Site Reaction 01/2018
1	Left Ventricular Dysfunction 01/2018
1	Body Weight Changes 04/2016
1	Metabolic Diseases (Metabolic Disease) 12/2015
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2015

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 11/2022 - 07/2010
9	oxidized low density lipoproteinIBA 06/2024 - 02/2013
8	LipidsIBA 03/2024 - 12/2015
8	Catechin (Z 7300)IBA 01/2018 - 06/2010
4	LDL CholesterolIBA 03/2024 - 01/2021
4	C-Reactive ProteinIBA 12/2023 - 02/2013
4	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2016 - 08/2011
3	CholesterolIBA 09/2023 - 01/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2018
3	Natriuretic PeptidesIBA 05/2012 - 07/2010
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2024 - 01/2020
2	Lipoproteins (Lipoprotein)IBA 03/2024 - 01/2018
2	IvabradineIBA 01/2021 - 01/2021
2	tofacitinibIBA 01/2021 - 01/2020
2	Proprotein Convertase 9IBA 12/2020 - 01/2018
2	Lipocalin-2IBA 05/2012 - 07/2010
2	CreatinineIBA 05/2012 - 04/2012
1	omega-Chloroacetophenone (Mace)IBA 04/2024
1	Lipoprotein(a)IBA 03/2024
1	ALN-PCSIBA 03/2024
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2023
1	HDL CholesterolIBA 09/2023
1	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 01/2023
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022
1	SolutionsIBA 01/2022
1	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	lipoprotein cholesterolIBA 01/2021
1	InflammasomesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CytokinesIBA 01/2021
1	succinic acid mono- (4- (18- (4- (3- carboxypropionyloxy)- 2,6,6- trimethyl- 3- oxocyclohex- 1- enyl)- 3,7,12,16- tetramethyloctadeca- 1,3,5,7,9,11,13,15,17- nonaenyl)- 3,5,5- trimethyl- 2- oxocyclohex- 3- enyl) esterIBA 12/2020
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	Janus Kinase InhibitorsIBA 01/2020
1	SymportersIBA 12/2019
1	SodiumIBA 12/2019
1	Insulin ReceptorIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	Triglycerides (Triacylglycerol)IBA 01/2018
1	alirocumabIBA 01/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2015
1	ProcalcitoninIBA 04/2014

Therapy/Procedure

7	Therapeutics 03/2024 - 07/2010
4	Drug Therapy (Chemotherapy) 06/2024 - 12/2019
4	Cardiac Rehabilitation 01/2023 - 01/2021
1	Blood Component Removal (Apheresis) 03/2024
1	Continuous Positive Airway Pressure 01/2023
1	Cardiac Resynchronization Therapy 09/2021
1	Continuity of Patient Care 03/2020